EMP-012 is under clinical development by Empirico and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData, Phase I drugs for Unspecified Immunological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EMP-012 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EMP-012 overview
Empirico overview
Empirico is a biotechnology company. Empirico develops transformative precision medicines for the treatment of common medicines. It offers the Precision Insights platform, a proprietary human genetics-focused discovery platform to identify and prioritize therapeutic targets. It also offers siRCH Platform for the design and discovery of clinically-viable siRNA lead candidates. The company’s platforms uncovers and mimicks favorable causal relationships between human genetic variation and clinical outcomes. Its platform utilize computational and experimental approaches to both discover novel targets and design therapeutic molecules. Empirico is headquartered in San Diego, California, the US.
For a complete picture of EMP-012’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
